Rafoxanide

Rafoxanide is a poent, orally active halogenated salicylaniline agent with antiparasitic activity. Rafoxanide interferes with energy metabolism in trematodes by uncoupling oxidative phosphorylation. Rafoxanide is also found to be a potent inhibitor of the BRAF V600E mutant protein, which is important in colorectal cancer. Rafoxanide can be used for the control of infestation with Hemonchus species or Fasciola species in sheep and cattle as well as Oestrus ovis in sheep. Rafoxanide can also be used for cancer research[1][2][3].

Product Specifications

CAS Number

[22662-39-1]

UNSPSC

12352005

Hazard Statement

H302, H413

Target

Apoptosis; Oxidative Phosphorylation; p38 MAPK; Parasite; Raf

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Rafoxanide.html

Purity

98.60

Solubility

DMSO : ≥ 31 mg/mL

Smiles

O=C(NC1=CC=C(OC2=CC=C(Cl)C=C2)C(Cl)=C1)C3=CC(I)=CC(I)=C3O

Molecular Formula

C19H11Cl2I2NO3

Molecular Weight

626.01

Precautions

H302, H413

References & Citations

[1]El-Banna HA, et, al. Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. Parasitol Res. 2008 May;102 (6) :1337-42.|[2]van Wyk JA, et, al. Two field strains of Haemonchus contortus resistant to rafoxanide. Onderstepoort J Vet Res. 1987 Jun;54 (2) :143-6.|[3]Laudisi F, et al. Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. Cancer Lett. 2019;462:1-11.